Trials / Not Yet Recruiting
Not Yet RecruitingNCT07264413
Bleeding Reduction in Grade II-III Haemorrhoids Through Embolization Treatment
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (estimated)
- Sponsor
- Cardiovascular and Interventional Radiological Society of Europe · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
BRIGHT is a Europe-wide study that will follow up to 250 adults with bleeding symptoms from haemmorhoids (Grade II-III categories). It aims to understand how well a minimally invasive procedure called haemorrhoid artery embolization (HAE) works in everyday clinical practice, which is a technique that blocks the blood vessels feeding the haemorrhoids. As this technique does not require major surgery, HAE offers several benefits such as less trauma, quicker recovery, and the use of only local anaesthesia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Haemorrhoid artery embolizsation (HAE) | Haemorrhoid artery embolization (HAE) is a minimally invasive procedure used to treat symptomatic haemorrhoids by reducing their blood supply. Under imaging guidance, typically fluoroscopy, a catheter is inserted through a small puncture in the groin or wrist and guided into the arteries that supply the haemorrhoidal tissue, known as the superior rectal arteries. Once the target vessels are identified, embolization coils-tiny metal coils designed to block blood flow-are placed inside these arteries. The coils create a controlled blockage, decreasing blood flow to the haemorrhoids, which helps shrink the swollen tissue and reduce bleeding. HAE is usually performed as an day-case procedure under local anaesthesia with mild sedation, and tends to result in less pain, quicker recovery, and lower complication rates compared to surgical approaches. |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2030-04-01
- Completion
- 2030-12-01
- First posted
- 2025-12-04
- Last updated
- 2025-12-04
Source: ClinicalTrials.gov record NCT07264413. Inclusion in this directory is not an endorsement.